secwatch.observer — SEC 8-K summary
======================================

Issuer:     BiomX Inc. (PHGE)
CIK:        0001739174
Form:       8-K
Filed at:   2023-02-22T23:59:59+00:00
Accession:  0001213900-23-013615
Event type: other_material
Sentiment:  positive
Materiality: 0.80
Item codes: 1.01, 3.02, 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

BiomX raises ~$7.5M in PIPE; reports positive Phase 1b/2a data for BX004 in CF
------------------------------------------------------------------------------

- Private placement of 30.6M shares at $0.245; gross proceeds ~$7.5M in two closings.
- First closing of ~$1.5M (5.98M securities) imminent; second closing contingent on shareholder approval.
- Part 1 Phase 1b/2a: BX004 reduced P. aeruginosa by -1.42 log10 CFU/g vs -0.28 placebo at Day 15.
- No safety events or emerging resistance; phages detected in all treated patients during dosing.
- Part 2 (24 patients) expected Q3 2023; proceeds to fund BX004 CF development and working capital.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/0001213900-23-013615-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1739174/000121390023013615/ea174091-8k_biomxinc.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-013615

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer